0001127602-22-011526.txt : 20220405 0001127602-22-011526.hdr.sgml : 20220405 20220405160815 ACCESSION NUMBER: 0001127602-22-011526 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220404 FILED AS OF DATE: 20220405 DATE AS OF CHANGE: 20220405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHEIBLER LUKAS CENTRAL INDEX KEY: 0001651281 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 22806840 MAIL ADDRESS: STREET 1: C/O APELLIS PHARMACEUTICALS, INC. STREET 2: 6400 WESTWIND WAY, SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-04-04 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001651281 SCHEIBLER LUKAS C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 CHIEF INNOVATION OFFICER Common Stock 2022-04-04 4 M 0 3504 13.85 A 55737 D Common Stock 2022-04-04 4 S 0 818 55.84 D 54919 D Common Stock 2022-04-04 4 S 0 1437 56.864 D 53482 D Common Stock 2022-04-04 4 S 0 1249 57.805 D 52233 D Stock Option (Right to Buy) 13.85 2022-04-04 4 M 0 3504 0 D 2029-02-07 Common Stock 3504 50000 D This is a scheduled exercise and sale from 10B5-1 trading plan. The sale price range within $1.00. Max. $55.21 - Min. $56.13 The sale price range within $1.00. Max. $56.34 - Min. $57.22 The sale price range within $1.00. Max. $57.37 - Min. $58.29. This represents a stock option grant made on 02/08/2019 that vests as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service. /s/ David Watson, attorney-in-fact for Lukas Scheibler 2022-04-05